Table 3.
Comparison of Antitumor Activity of ABT-751 Plus Pemetrexed Versus Placebo Plus Pemetrexed
| Parameter | All Patients |
Nonsquamous NSCLC |
Squamous Cell NSCLC |
|||
|---|---|---|---|---|---|---|
| ABT-751 + Pemetrexed (n = 83) | Placebo + Pemetrexed (n = 82) | ABT-751 + Pemetrexed (n = 58) | Placebo + Pemetrexed (n = 62) | ABT-751 + Pemetrexed (n = 25) | Placebo + Pemetrexed (n = 20) | |
| Median PFS, months | 2.3 | 1.9 | 2.3 | 2.6 | 2.7 | 1.4 |
| HR* | 0.97 | 1.16 | 0.58 | |||
| 95% CI | 0.65 to 1.46 | 0.73 to 1.82 | 0.30 to 1.15 | |||
| P by log-rank test† | .819 | .534 | .112 | |||
| Median OS, months | 8.1 | 6.7 | 8.5 | 8.2 | 8.1 | 3.3 |
| HR* | 0.84 | 1.08 | 0.47 | |||
| 95% CI | 0.55 to 1.27 | 0.68 to 1.72 | 0.23 to 0.96 | |||
| P by log-rank test† | .410 | .742 | .034 | |||
Abbreviations: NSCLC, non–small-cell lung cancer; PFS, progression-free survival; HR, hazard ratio; OS, overall survival.
*
Based on stratified Cox proportional hazards regression model comparing two treatment groups for all patients analysis and unstratified Cox proportional hazards model comparing two treatment groups in the subgroups of patients with nonsquamous NSCLC and squamous NSCLC.
†
Based on stratified log-rank test comparing two treatment groups for all patients analysis and unstratified log-rank test comparing two treatment groups in the subgroups on patients with nonsquamous NSCLC and squamous NSCLC.